Pre-made Eculizumab benchmark antibody ( Whole mAb, anti-C5/CO5 therapeutic antibody, Anti-CPAMD4/ECLZB Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Eculizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Eculizumab, sold under the brand name Soliris among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted based on small trials.[2][3][4][5] It is given in a clinic by intravenous (IV) infusion.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-164-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Eculizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody
INN Name	Eculizumab
Target	CO5
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	5i5k:HL:XY
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2002
Year Recommended	2003
Companies	Alexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc
Conditions Approved	Neuromyelitis optica;Haemolytic uraemic syndrome;Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria
Conditions Active	Delayed graft function;Guillain-Barre syndrome;Renal transplant rejection;COVID-19
Conditions Discontinued	Antiphospholipid syndrome;Heart transplant rejection;Adult respiratory distress syndrome;Age-related macular degeneration;Allergic asthma;Autoimmune haemolytic anaemia;Bullous pemphigoid;Dermatomyositis;Glomerulonephritis;Idiopathic thrombocytopenic purpura;Lupus nephritis;Membranous glomerulonephritis;Motor neuron disease;Psoriasis;Rheumatoid arthritis;Systemic lupus erythematosus
Development Tech	GS Gene Expression System